Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GOSS 
Gossamer Bio Inc (GOSS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: GOSS (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9
1 Year Target Price $9
| 4 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.94% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 567.62M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 9 | Beta 1.95 | 52 Weeks Range 0.66 - 3.60 | Updated Date 10/25/2025 |
52 Weeks Range 0.66 - 3.60 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -337.41% |
Management Effectiveness
Return on Assets (TTM) -29.63% | Return on Equity (TTM) -783.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 557538910 | Price to Sales(TTM) 14.11 |
Enterprise Value 557538910 | Price to Sales(TTM) 14.11 | ||
Enterprise Value to Revenue 13.86 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 228880609 | Shares Floating 183248307 |
Shares Outstanding 228880609 | Shares Floating 183248307 | ||
Percent Insiders 3.95 | Percent Institutions 77.47 |
Upturn AI SWOT
Gossamer Bio Inc
Company Overview
History and Background
Gossamer Bio, Inc. was founded in 2017 and is headquartered in San Diego, California. It is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
Core Business Areas
- Immunology: Focuses on developing treatments for autoimmune and inflammatory diseases.
- Oncology: Developing therapies targeting cancer.
Leadership and Structure
Faheem Hasnain serves as the Chairman, CEO, and Co-Founder. The company has a typical organizational structure for a publicly traded biopharmaceutical company, with departments such as Research and Development, Clinical Operations, Regulatory Affairs, and Commercial Operations. In November 2023, the Company announced that the Board of Directors determined to discontinue active clinical development of GB004 and other pipeline programs, conduct a strategic review, and significantly reduce its workforce.
Top Products and Market Share
Key Offerings
- GB004: Was a clinical-stage, oral prostaglandin DP2 receptor antagonist being developed for eosinophilic asthma, but development was discontinued in 2023. Competitors included AstraZeneca and Teva Pharmaceutical.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy development timelines, and regulatory hurdles. The industry is highly competitive, with numerous companies vying to develop innovative therapies.
Positioning
Gossamer Bio aimed to be a player in the immunology and oncology spaces, but its current position is weakened following pipeline setbacks and strategic review.
Total Addressable Market (TAM)
The total addressable market for immunology and oncology therapies is significant, valued in the hundreds of billions of dollars annually. Gossamer Bio's position regarding the TAM is currently weak due to the pipeline setbacks
Upturn SWOT Analysis
Strengths
- Experienced management team
- Cash balance
Weaknesses
- Pipeline setbacks
- Lack of approved products
- High cash burn rate
- Small Market Cap
Opportunities
- Potential for strategic partnerships
- Re-evaluate existing pipeline and partnerships
- Asset sales
Threats
- Clinical trial failures
- Regulatory challenges
- Competition from larger pharmaceutical companies
- Financing risk
Competitors and Market Share
Key Competitors
- AZN
- TEVA
Competitive Landscape
Gossamer Bio is in a challenging position relative to its competitors. AZN and TEVA are significantly larger and have diversified product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by pipeline progress, but recent setbacks have altered the growth trajectory.
Future Projections: Future growth projections are highly uncertain given the company's strategic review. Analyst estimates are likely to be revised or unavailable.
Recent Initiatives: The most recent initiative is a strategic review involving discontinuing active clinical development of GB004 and other pipeline programs.
Summary
Gossamer Bio is currently undergoing a strategic review following pipeline setbacks, significantly altering its future. The company's previous focus was on developing therapies for immunology, inflammation, and oncology. With a history of R&D investment and no approved products, they're now reassessing strategic alternatives. Investors should exercise caution, and monitor announcements closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Gossamer Bio SEC Filings
- Company Website
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Financial data is subject to change. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gossamer Bio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2019-02-08 | Co-Founder, CEO, President & Chairman Mr. Faheem Hasnain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 144 | Website https://www.gossamerbio.com |
Full time employees 144 | Website https://www.gossamerbio.com | ||
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.